Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript

SA Transcripts158.39K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call February 11, 2026 4:30 PM EST Company Participants Kevin Moran - Senior VP, CFO & TreasurerMihael Polymeropoulos - Founder, President, CEO & Chairman of The Board Conference Call Participants Madison Wynne El-Saadi - B. Riley Securities, Inc., Research DivisionRaghuram Selvaraju - H.C. Wainwright & Co, LLC, Research DivisionSamuel Rodriguez - Cantor Fitzgerald & Co., Research DivisionLin Tsai - Jefferies LLC, Research Division Presentation Operator Thank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome Vanda Pharmaceuticals Inc.

Earnings Conference Call. [Operator Instructions] Thank you. I'd now like to turn the call over to Kevin Moran, Vanda's Chief Financial Officer. Please go ahead. Kevin MoranSenior VP, CFO & Treasurer Thank you, Jordan. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals' Fourth Quarter and Full Year 2025 performance. Our fourth quarter and full year 2025 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer and Chairman of the Board; and Tim Williams, our General Counsel. Following my introductory remarks, Mihael will update you on our ongoing activities. I will then comment on our financial results before we open the lines for your questions. Before we proceed, I would like to remind everyone that various statements that we make on this call will be forward-looking statements within the meaning of federal securities laws. Our forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. These risks are described in the cautionary